Updated:
Becton
Becton, Dickinson and Company was founded in 1907 by Maxwell Becton and Fairleigh Dickinson and has operated for over a century from its headquarters in...
Becton
Becton, Dickinson and Company was founded in 1907 by Maxwell Becton and Fairleigh Dickinson and has operated for over a century from its headquarters in Franklin Lakes, New Jersey. The firm is a publicly held global medical technology company whose investment activity is a function of its corporate development arm, not a separate asset management vehicle. Chairman and CEO Tom Polen has led the company since early 2020, overseeing a strategy built around smart connected devices, robotic pharmacy automation, and advanced diagnostics. The company's capital deployment takes the form of outright acquisitions rather than traditional fund commitments or co-investments. Becton's $25.8 billion purchase of C.R. Bard in 2017 expanded its footprint into vascular access and surgical devices, and the firm continues to absorb smaller technology targets to fill product-line gaps. Recent examples include the acquisitions of Pharmacy Automation platform assets and the surgical sealant firm Tissuemed, as well as a $4.2 billion deal for infusion pump maker CareFusion. The investment lens remains narrowly focused on medtech — specifically medication management, infection prevention, and specimen collection — with commercial operations in over 50 countries across the Americas, Europe, and Asia Pacific. Becton operates approximately 30 manufacturing and R&D facilities worldwide and maintains a professional workforce exceeding 70,000 employees. The company does not operate a philanthropic foundation, but in April 2022 it executed a spinoff of its diabetes care business into a separate public company, Embecta Corp., unlocking an independent vehicle for investors with a different risk-return profile from Becton's core diagnostic and interventional businesses. By regulatory posture, Becton functions as a taxpaying C-corporation whose investment decisions run through a standard corporate M&A process rather than an independent investment committee. Its investment capacity is tied to the price of its publicly traded equity and the discipline of its operating cash flows — a structure that makes it fundamentally unlike a family office, where asset allocation responds to a single family's liquidity needs.
General information
Firm type
Asset Manager
Year founded
1907
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Franklin Lakes
Corporate office
Franklin Lakes, NJ, United States
Principals
Tom Polen
Chairman, CEO and President
Sector focus
Frequently asked questions
Is Becton structured as a family office?
No. Becton is a publicly traded medical technology company (NYSE: BDX) governed by a board of directors and operated for the benefit of all shareholders. Founded in 1907 by Maxwell Becton and Fairleigh Dickinson, the company has not functioned as a single-family investment vehicle for multiple generations. Its investment activity is corporate M&A executed by the firm's internal corporate development function.
Who runs investment decisions at Becton?
Capital-allocation decisions at Becton are made through a standard corporate governance structure: the CEO and leadership team prepare strategic acquisition proposals that require board approval. Tom Polen has served as Chairman and CEO since 2020 and is the primary executive responsible for shaping the firm's acquisition pipeline. The company does not maintain a separate investment committee akin to a family office or asset manager.
Does Becton participate in fund commitments or only direct deals?
Becton does not make fund commitments or participate in commingled investment vehicles. The company acts solely as a strategic acquirer, purchasing operating businesses and technology platforms outright. All observed transactions are direct corporate acquisitions requiring full consolidation into Becton's financial statements.
How does Becton source its acquisition targets?
Becton sources acquisition targets through its internal corporate development and business-unit leadership teams, which maintain relationships across the medtech, diagnostics, and life-sciences sectors. The company acquires primarily in spaces adjacent to its existing product lines — medication management, infection prevention, and specimen collection — and relies on its own operating expertise rather than external GP relationships for due diligence.
What investment stages does Becton typically target?
Becton acquires established commercial-stage companies with proven revenue streams and FDA-cleared products. It does not pursue seed-stage, venture, or growth-equity investments in the traditional sense. All observed transactions — from CareFusion ($4.2B) to Tissuemed to Pharmacy Automation assets — represent acquisitions of companies already generating revenue that can be integrated into Becton's global distribution channels.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: